Details of the Drug

General Information of Drug (ID: DMTE8DC)

Drug Name
Pozelimab
Synonyms REGN3918
Indication
Disease Entry ICD 11 Status REF
N.A. Approved [1]
Paroxysmal nocturnal haemoglobinuria 3A21.0 Phase 2 [2]
Drug Type
Antibody
Cross-matching ID
DrugBank ID
DB15218
TTD ID
D4XBR9
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Complement C5 (CO5) TTKANGO CO5_HUMAN Inhibitor [3]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease
ICD Disease Classification
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Complement C5 (CO5) DTT C5 7.69E-01 -0.12 -0.23
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 761339
2 ClinicalTrials.gov (NCT04888507) Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy. U.S. National Institutes of Health.
3 Inhibition of complement pathway activation with Pozelimab, a fully human antibody to complement component C5. PLoS One. 2020 May 8;15(5):e0231892.